52
Participants
Start Date
January 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
June 30, 2014
Maraviroc
For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
placebo
For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
University of California, San Francisco, San Francisco
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Pfizer
INDUSTRY
University of California, San Francisco
OTHER